Cell Therapeutics (CTIC +10.9%) rose the biggest intraday rise since Dec. 6, to $1.12. The Food and Drug Administration said the company’s pixantrone, which is under review for adults with non-Hodgkin’s lymphoma who received two or more prior lines of therapy,rallies after the FDA says the company's drug pixantrone, which is under review for adults with non-Hodgkin's lymphoma, will be discussed by an advisory committee in early February. by an advisory committee on Feb. 9.
For the latest updates on the stock market, visit,
http://daytradingstock-blog.blogspot.com/
